Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
Quick facts
Marketed products
- LATANOPROST 0.005% EYEDROPS
- Latanoprost, Dorzolamide · Ophthalmology
This combination reduces intraocular pressure by increasing uveoscleral outflow of aqueous humor (latanoprost) and decreasing aqueous humor production (dorzolamide). - TAFLUPROST 0.0015% EYEDROPS
Phase 3 pipeline
- Betaine taurine PVP gel · Dermatology / Wound Care
Betaine and taurine in a PVP gel formulation work synergistically to promote wound healing and tissue repair through osmotic and cytoprotective effects. - Cisplatin plus Etoposide · Oncology
Cisplatin and etoposide work together as chemotherapy agents—cisplatin cross-links DNA to prevent replication, while etoposide inhibits topoisomerase II to block DNA unwinding and repair. - RASS inhibitors and/or RAS blockers · Cardiovascular
RASS inhibitors and RAS blockers suppress the renin-angiotensin-aldosterone system to reduce vasoconstriction, lower blood pressure, and decrease sodium retention. - Xylitol, Lactoperoxidase, Lysozyme, Lactoferrin · Oral Health
Xylitol inhibits bacterial adhesion and biofilm formation, while Lactoperoxidase, Lysozyme, and Lactoferrin have antimicrobial properties.
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
- Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia portfolio CI brief
- Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia pipeline updates RSS
Frequently asked questions about Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
What are Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia's marketed drugs?
Top marketed products include LATANOPROST 0.005% EYEDROPS, Latanoprost, Dorzolamide, TAFLUPROST 0.0015% EYEDROPS.
What is Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia's pipeline?
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia has 4 drugs in Phase 3, 0 in Phase 2, 0 in Phase 1. Late-stage candidates include Betaine taurine PVP gel, Cisplatin plus Etoposide, RASS inhibitors and/or RAS blockers, Xylitol, Lactoperoxidase, Lysozyme, Lactoferrin.
Related
- LATANOPROST 0.005% EYEDROPS
- Latanoprost, Dorzolamide · Ophthalmology
- TAFLUPROST 0.0015% EYEDROPS
- Sector hub: All tracked pharma companies